CDH1 and metastatic prostate carcinoma: These findings were confirmed by a subsequent study providing clear evidence that CDH1 loss sensitizes to DNA damage and causes a synthetic lethal response to DNA damaging therapy in vitro, in vivo, ex vivo, in patient-derived organoid cultures, and in a patient with metastatic prostate cancer [148].